Zynerba Stock Analysis 2017: Profiting Off Marijuana Pharmaceuticals

Zynerba Stock Fundamental Analysis: Zynerba Pharmaceuticals experienced a strong pullback after the company announced an offering of an additional 2.8 million shares of Zynerba Stock at $18. This scared off many investors and traders, which pushed the price straight down to $18 per share. However, today the stock kicked back into action ending the day up […]

Continue reading

GNC Stock Analysis For 2017: Is Bankruptcy Inevitable At This Point?

gnc stock analysis

GNC Stock Analysis 2017 Shares of GNC holdings plummeted today after Goldman Sachs downgraded the company and gave it a price target of eight dollars per share. This caused the stock to tank approximately 17%. Without a doubt, this reaction is extreme and uncommon for a simple downgrade. So, I decided it would be a good […]

Continue reading

Page 3 of 10
1 2 3 4 5 10